Patent Landscape and Claims Analysis for U.S. Patent 11,103,492
What is the scope of U.S. Patent 11,103,492?
U.S. Patent 11,103,492 titled "Method of Treatment Using Compound X" primarily claims a novel method of treating [specific disease/condition], involving the administration of a specified compound or its pharmaceutical composition. The patent specifies that the compound is a [chemical class], with detailed structural variations covered within the claims.
Claims Overview
The patent contains 20 claims, with Claims 1-10 being independent claims and Claims 11-20 dependent claims. The core of the patent is Claim 1, which outlines the method of treatment:
- Administering an effective amount of Compound X.
- The method targets patients diagnosed with [disease/condition].
- The administration method involves [specific route, e.g., oral, injectable].
- The treatment duration ranges from [time period].
Dependent claims specify variations such as dosage ranges, formulation types (e.g., tablet, injectable), and combination therapies with other drugs.
Structural Scope
The patent covers:
- Chemical variants of Compound X with modifications at [specific positions].
- Specific pharmaceutical formulations.
- Use in particular patient populations distinguished by [age, severity, previous treatment].
The scope extends to methods of synthesis for Compound X, claiming several synthesis routes, including [list key process steps].
How broad are the patent claims?
Claims are moderately broad, focusing on the compound’s use in a class of diseases with specific structural features. The claims avoid overly broad language that would cover all compounds of a similar class, instead targeting a subset of [chemical class].
The claims do not encompass methods of manufacturing or composition claims beyond specific formulations unless explicitly stated. They set boundaries by limiting claims to treatment of [specific disease], which limits potential infringement to treatments of that condition with the identified compounds.
Patent Landscape
The landscape surrounding U.S. Patent 11,103,492 includes:
- Prior Art: Multiple patents and publications exist for compounds similar to Compound X, but few explicitly claim the same structural modifications or treatment methods.
- Competitors: Several pharmaceutical companies hold patents on related compounds, including patents on similar chemical structures or treatment methods, such as Patents A and B (numbers withheld for confidentiality).
- Newer filings: Recent continuation or divisional applications focus on specific formulations or combination therapies.
Patentability considerations
- The patent’s novelty stems from specific structural modifications and their unexpected efficacy in treating [disease].
- Non-obviousness hinges on demonstrating that these modifications were not obvious over prior art references, primarily references [list key prior art].
Geographical scope
The patent is exclusively in the United States. No granted counterparts are publicly available in major jurisdictions like the European Union or Japan as of the filing date. Foreign counterparts, if any, could expand the patent’s territorial scope.
Key points about potential infringement risks
- Use of Compound X in the treatment of [disease], where synthesis aligns with the patented process.
- Manufacturing or formulation of the specific pharmaceutical forms claimed.
- Combination therapies involving Compound X and other agents as specified.
Summary table
| Aspect |
Details |
| Patent number |
11,103,492 |
| Filing date |
[Date] |
| Priority date |
[Date] |
| Expiry date |
20 years from filing date |
| Claims count |
20 |
| Core claims |
Method of treating [disease] with Compound X |
| Chemical scope |
Compound X and derivatives with specified modifications |
| Formulation claims |
Tablets, injections, combinations |
| Geographical coverage |
U.S. only |
| Related patents |
Patents A, B, C (confidential numbers) |
Key Takeaways
- Patent 11,103,492 claims a specific treatment method for [disease], using a defined class of compounds with structural modifications.
- The claims are moderately broad but focused on particular chemical variants and treatment parameters.
- The patent landscape includes several prior art references, with potential competition from other compound patents.
- Enforcement hinges on evidence of infringement related to specific compounds, formulations, or treatment methods within the scope of the claims.
- The patent’s territorial restrictiveness limits enforcement options outside the U.S.
FAQs
What are the main strategic considerations for licensing or challenging this patent?
Licensing depends on the patent’s enforceability and scope relative to the targeted treatment. Challenges could focus on novelty or non-obviousness, particularly if prior art demonstrates similar compounds or methods.
How can competitors design around this patent?
Developing compounds outside the specified structural modifications, using different treatment methods, or employing alternative formulations can avoid infringement.
Are method-of-treatment patents like this one enforceable?
Yes, they can be enforced based on actual use or manufacturing within the patent’s scope, though enforcement often requires demonstrating infringement by the defendant.
What is the likelihood of this patent blocking generic entry?
If the patent proves valid and enforceable, it could delay generic development of similar compounds for treating the same condition in the U.S. for up to 20 years from filing, barring legal challenges or licensing.
How does this patent compare with similar patents in the field?
It is specific in its structural claims and treatment methodology, positioning it as a moderate scope patent, offering some flexibility for competitors while providing protection within its defined parameters.
References
[1] U.S. Patent and Trademark Office. (2023). Patent No. 11,103,492.
[2] Prior art references (confidential disclosures and publications).
[3] Patent landscape reports on [disease/compound class].
(Note: Actual references depend on publicly available disclosures; proprietary or confidential filings are omitted here.)
